Priors rates this Established — 92 out of 100, updated weekly. Yes — this looks well established. On the claim that ceftazidime-avibactam is effective against KPC- and OXA-48-producing Enterobacterales and is superior to colistin-based regimens for carbapenem-resistant infections, but lacks activity against metallo-beta-lactamase (MBL)-producing organisms (NDM, VIM, IMP), its four-agent AI review panel weighs 7 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Antimicrobial Resistance Novel Antibiotics review.